Skip to main content
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week for 24 weeks
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
// //

The Johnson & Johnson logo is displayed at the New York Stock Exchange on Sept. 17, 2019.

BRENDAN MCDERMID/Reuters

Johnson & Johnson raised its annual profit forecast for the second time this year in quarterly results on Tuesday, a day after it was the second major drug company to call a temporary halt to trials of its experimental coronavirus vaccine.

With shares in the company falling on investor worries about the fate of the vaccine, finance chief Joseph Wolk said it was unclear how long the suspension in the trials, due to an unexplained illness of one participant, would last.

“It could be as small as a few days but it’s hard to predict until they get the information they need,” he told CNBC.

Story continues below advertisement

Johnson & Johnson said on Monday it had temporarily paused its COVID-19 vaccine candidate clinical trials due to an unexplained illness in a study participant, delaying one of the highest profile efforts to contain the global pandemic. Reuters

The company will let an independent data and safety board go through its protocols as it reviewed the illness, he said.

Johnson & Johnson is the first major U.S. drugmaker and medical device manufacturer to report third-quarter results and its earnings could set the tone for upcoming rival’s earnings.

In the third quarter, sales rose to $21.08 billion from $20.73 billion, helped by strength in the company’s largest unit, pharmaceuticals.

Sales of cancer drug Darzalex rose 43.7 per cent to $1.10 billion.

Sales of Imbruvica, which J&J jointly owns with AbbVie Inc , as well as Crohn’s disease drug Stelara, grew in the double-digits, bringing in $1.03 billion and $1.95 billion respectively.

Its medical device unit’s sales fell 3.6 per cent to $6.15 billion, as patients and hospitals continued to delay non-urgent surgeries due to the COVID-19 pandemic.

The company now expects full-year 2020 adjusted profit of $7.95 to $8.05 per share, from its prior range of $7.75 to $7.95 per share.

Story continues below advertisement

On an adjusted basis, the company earned $2.20 per share, beating analysts' estimates of $1.98 per share, according to IBES data from Refinitiv.

J&J’s shares fell 1.7 per cent to $149.25 before the bell.

Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies